ArticleArchives of toxicology2026
Sex-specific toxicity targets of aristolochic acids: nephrotoxicity in males, hepatotoxicity in females.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of immune dysregulation in aristolochic acid-induced multisystem toxicities: an insight from systems toxicology.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aristolochic acids (AAs), derived from Aristolochia herbs, are well-known nephrotoxins, and emerging evidence suggests their potential role in the development of liver cancers. However, the specific organs most affected by AAs, particularly in relation to liver cancer, remain unclear. Considering the known sex differences in enzyme activities, we hypothesized that variations in AA metabolism may contribute to the kidney and liver toxicity associated with these compounds. Our analysis of DNA adducts in the kidneys and livers of mice treated with aristolochic acid I (AA-I) revealed that male mice exhibited over 2.5 times higher levels of DNA adducts in their kidney DNA compared to female mice. Conversely, female mice showed 1.5 times higher adduct levels in their liver DNA than their male counterparts. These findings indicate that AA exposure presents a sex-specific disease risk, with males being at greater risk for kidney disease and females for liver disease. Additionally, we observed similar concentration patterns of the metabolite aristolactam I (AL-I) and the activity of NQO1 enzymes in the respective organs. Further in vitro studies, involving the incubation of AA-I with liver and kidney homogenates, demonstrated significant differences in AL-I concentrations, mirroring the trends observed in the AA-DNA adduct and AL-I analyses of AA-I-exposed mice. Collectively, these results underscore the importance of sex differences in the enzymatic activity responsible for the metabolic activation of AAs, which is critical for understanding the differential nephrotoxic and hepatotoxic effects associated with these compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.